Abstract
Breast cancer is the most common cancer in women in the United States. The treatment of breast cancer has multiple side effects, including cancer-related fatigue (CRF). While physical activity has the strongest evidence in treating CRF, it is limited by a patient’s functional status, disease, and safety concerns. Several studies have demonstrated that exogenous melatonin has improved depressive symptoms, insomnia, and sleep quality in breast cancer patients. However, few have focused on the effects of melatonin on CRF. This review explores the effect of melatonin on CRF in breast cancer patients. A review of current literature was conducted by searching PubMed, Cochrane, Scopus, and CINAHL databases. One hundred articles resulted, and after applying exclusion criteria, five articles were chosen for this review. Results showed a significant improvement in CRF in the studies utilizing 5 mg and 18 mg of melatonin in breast cancer patients undergoing chemotherapy or radiation. Melatonin can be considered an option for patients with breast cancer experiencing CRF, especially in the context of patients with physical limitations where exercise may not be an option. Additional research is needed to further evaluate the role and ideal dose of melatonin in the management of CRF.
References
American Cancer Society. (2025). Cancer Facts and Figures 2025. American Cancer Society. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2025-cancer-facts-figures.html
American Cancer Society. (2024). What is Fatigue or Weakness? American Cancer Society. https://www.cancer.org/cancer/managing-cancer/side-effects/fatigue/what-is-cancer-related-fatigue.html
Bower, J. E., Ganz, P. A., Desmond, K. A., Rowland, J. H., Meyerowitz, B. E., & Belin, T. R. (2000). Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. Journal of Clinical Oncology, 18(4), 743–743. https://doi.org/10.1200/jco.2000.18.4.743
Erland, L. A. E., & Saxena, P. K. (2017). Melatonin natural health products and supplements: Presence of serotonin and significant variability of melatonin content. Journal of Clinical Sleep Medicine, 13(02), 275–281. https://doi.org/10.5664/jcsm.6462
Fisher, M. I., Cohn, J. C., Harrington, S. E., Lee, J. Q., & Malone, D. (2022). Screening and assessment of cancer-related fatigue: A clinical practice guideline for Health Care Providers. Physical Therapy, 102(9). https://doi.org/10.1093/ptj/pzac120
Hansen, M. V., Andersen, L. T., Madsen, M. T., Hageman, I., Rasmussen, L. S., Bokmand, S., Rosenberg, J., & Gögenur, I. (2014). Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: A randomized, double-blind, placebo-controlled trial. Breast Cancer Research and Treatment, 145(3), 683–695. https://doi.org/10.1007/s10549-014-2962-2
Innominato, P. F., Lim, A. S., Palesh, O., Clemons, M., Trudeau, M., Eisen, A., Wang, C., Kiss, A., Pritchard, K. I., & Bjarnason, G. A. (2015). The effect of melatonin on sleep and quality of life in patients with Advanced Breast Cancer. Supportive Care in Cancer, 24(3), 1097–1105. https://doi.org/10.1007/s00520-015-2883-6
Liu, J., Clough, S. J., Hutchinson, A. J., Adamah-Biassi, E. B., Popovska-Gorevski, M., & Dubocovich, M. L. (2016). MT1 and MT2 melatonin receptors: A therapeutic perspective. Annual Review of Pharmacology and Toxicology, 56(1), 361–383. https://doi.org/10.1146/annurev-pharmtox-010814-124742
Minton, O., Richardson, A., Sharpe, M., Hotopf, M., & Stone, P. (2008). A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. JNCI: Journal of the National Cancer Institute, 100(16), 1155–1166. https://doi.org/10.1093/jnci/djn250
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097
Mukhopadhyay, N. D., Khorasanchi, A., Pandey, S., Nemani, S., Parker, G., Deng, X., Arthur, D. W., Urdaneta, A., & Del Fabbro, E. (2023). Melatonin supplementation for cancer-related fatigue in patients with early stage breast cancer receiving radiotherapy: A double-blind placebo-controlled trial. The Oncologist, 29(2). https://doi.org/10.1093/oncolo/oyad250
National Comprehensive Cancer Network. (2024a). NCCN Clinical Practice Guidelines in Oncology: Cancer-related fatigue. https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf.
National Comprehensive Cancer Network. (2024b). NCCN Clinical Practice Guidelines in Oncology: Survivorship. https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf
Sedighi Pashaki, A., Mohammadian, K., Afshar, S., Gholami, M. H., Moradi, A., Javadinia, S. A., & Keshtpour Amlashi, Z. (2021). A randomized, controlled, parallel-group, trial on the effects of melatonin on fatigue associated with breast cancer and its adjuvant treatments. Integrative Cancer Therapies, 20, 153473542098834. https://doi.org/10.1177/1534735420988343
Sedighi Pashaki, A., Sheida, F., Moaddab Shoar, L., Hashem, T., Fazilat-Panah, D., Nemati Motehaver, A., Ghanbari Motlagh, A., Nikzad, S., Bakhtiari, M., Tapak, L., Keshtpour Amlashi, Z., Javadinia, S. A., & Keshtpour Amlashi, Z. (2023). A randomized, controlled, parallel-group, trial on the long-term effects of melatonin on fatigue associated with breast cancer and its adjuvant treatments. Integrative Cancer Therapies, 22, 153473542311686. https://doi.org/10.1177/15347354231168624
